Fate Therapeutics (FATE) Total Current Liabilities (2012 - 2026)

Fate Therapeutics has reported Total Current Liabilities for 15 years, with the latest figure at $30.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 8.98% year-over-year to $30.7 million; the trailing twelve-month figure through Mar 2026 stood at $30.7 million (up 8.98% YoY), and the FY2025 full-year result was $36.1 million, down 6.36% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $30.7 million, down from $36.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $114.1 million in Q4 2022, with the low at $28.1 million in Q3 2025.
• Historically, Total Current Liabilities has averaged $51.1 million across 5 years, with a median of $39.1 million in 2023.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 40.31% — and 2023, when it tumbled 65.72%.
• Fate Therapeutics' Total Current Liabilities stood at $114.1 million in 2022, then plunged by 65.72% to $39.1 million in 2023, then declined by 1.46% to $38.5 million in 2024, then slipped by 6.36% to $36.1 million in 2025, then retreated by 14.92% to $30.7 million in 2026.
• The last three Total Current Liabilities figures came in at $30.7 million (Q1 2026), $36.1 million (Q4 2025), and $28.1 million (Q3 2025), per Business Quant data.